ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tegoprazan

Also written as “Tegoprazan”, “Tegoprazan 50 mg” and “BLI5100”.

Its studies are mostly in Esophagitis · Non-Erosive Reflux Disease · Gastroesophageal Reflux · Peptic Ulcer · Duodenal Ulcer, led by 4 companies.

Drug pageTegoprazan: every studyAll 62 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 13, 202048 company-led studies, 7 open or runningNext primary completion: Jan 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HK inno.N376 open or runningphase 4since Mar 13, 2020Nov 14, 2011Jan 31, 2027phase 1 · NCT07853248
Shandong Luoxin Pharmaceutical Group Stockits history only70 open or runningphase 3since Jul 9, 2018Jan 25, 2018none ahead
Sebela Pharmaceuticalsits history only30 open or runningphase 3since Oct 17, 2022Oct 17, 2022none ahead
Carnot Laboratoriesits history only11 open or runningphase 4since May 20, 2025May 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of HK inno.N only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 22 earlier studies, Nov 14, 2011 to Nov 19, 2019.

  1. Jun 9, 2015Named tegoprazanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BLI5100
  2. Jan 6, 20202 phase 1 studies in HealthyNCT04221321, NCT04231136
  3. Mar 13, 2020Phase 4 study in Erosive Reflux DiseaseNCT04309916 · 46 enrolled · Korea, Republic of
  4. Jul 28, 2020Phase 1 study in Hepatic ImpairmentNCT04494269 · 28 enrolled · Korea, Republic of
  5. Nov 16, 2020Phase 1 study in HealthyNCT04639804 · 60 enrolled · Korea, Republic of
  6. Apr 7, 2021Phase 3 study in Preventive Peptic UlcerNCT04840550 · 392 enrolled · South Korea
  7. Jul 6, 2021Phase 4 study in Erosive Reflux DiseaseNCT05267743 · 218 enrolled · Korea, Republic of
  8. Apr 25, 2022Phase 1 study in HealthyNCT05353010 · 12 enrolled · Korea, Republic of
  9. Jan 18, 2023Phase 4 study in Gastroesophageal RefluxNCT05701540 · 338 planned · Korea, Republic of
  10. Feb 2, 2023Phase 1 study in HealthyNCT05723510 · 87 enrolled · Korea, Republic of
  11. May 23, 2023Phase 2 study in Helicobacter Pylori InfectionNCT05933031 · 381 planned · Korea, Republic of
  12. Dec 1, 2023Phase 1 study in HealthyNCT06164834 · 48 planned · Korea, Republic of
  13. Feb 20, 2024Phase 1 study in HealthyNCT06332638 · 36 planned · Korea, Republic of
  14. Sep 13, 2026Phase 4 study in Gastroesophageal RefluxNCT07826455 · 100 planned
  15. Sep 14, 2026Phase 1 study in Healthy Adult MaleNCT07853248 · 34 planned · South Korea

Ahead

  1. Jan 31, 2027Primary completion: phase 1 study in Healthy Adult MaleNCT07853248
  2. Jul 31, 2028Primary completion: phase 4 study in Gastroesophageal RefluxNCT07826455

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 37 HK inno.N leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07853248Healthy Adult Male · South Korea1Not yet recruitingJan 31, 202734
NCT07826455Gastroesophageal Reflux4Not yet recruitingJul 31, 2028100
NCT06332638Healthy · Korea, Republic of1By invitationJul 31, 202436
NCT06164834Healthy · Korea, Republic of1Not yet recruitingNov 202448
NCT05933031Helicobacter Pylori Infection · Korea, Republic of2RecruitingDec 31, 2024381
NCT05723510Healthy · Korea, Republic of1CompletedJul 17, 202387
NCT05701540Gastroesophageal Reflux · Korea, Republic of4RecruitingDec 31, 2024338
NCT05353010Healthy · Korea, Republic of1UNKNOWNJul 1, 202212
NCT05267743Erosive Reflux Disease · Korea, Republic of4CompletedMay 25, 2022218
NCT04840550Preventive Peptic Ulcer · South Korea3CompletedJul 1, 2025392
NCT04639804Healthy · Korea, Republic of1CompletedJul 26, 202060
NCT04494269Hepatic Impairment · Korea, Republic of1UNKNOWNJun 202328
NCT04309916Erosive Reflux Disease · Korea, Republic of4CompletedNov 30, 202146
NCT04231136Healthy · Korea, Republic of1CompletedJul 29, 202019
NCT04221321Healthy · Korea, Republic of1CompletedMar 12, 202032
NCT04171687Healthy · Korea, Republic of1CompletedFeb 7, 202036
NCT04128917Helicobacter Pylori Infection · Korea, Republic of3CompletedDec 21, 2020102
NCT04066257Healthy · Korea, Republic of1CompletedFeb 22, 201932
NCT04022096Healed Erosive Esophagitis · Korea, Republic of3CompletedJun 23, 2021351
NCT03863938Healthy · Korea, Republic of1CompletedApr 26, 201912
NCT03814642Healthy · Korea, Republic of1CompletedJul 22, 201925
NCT03530228Pharmacodynamics · Korea, Republic of1UNKNOWNAug 201844
NCT03498456Helicobacter Pylori Infection · Korea, Republic of3CompletedDec 31, 2019284
NCT03378284Pharmacodynamics · Korea, Republic of1CompletedDec 23, 201716
NCT03317223Helicobacter Pylori Infection · Korea, Republic of3CompletedJan 21, 2019350
NCT03043521Healthy · Korea, Republic of1CompletedAug 12, 201524
NCT03009760Healthy1CompletedApr 201616
NCT03011996Drug Interaction · Korea, Republic of1CompletedFeb 201760
NCT02995239Erosive Esophagitis · Korea, Republic of1CompletedApr 201512
NCT03006874Erosive Esophagitis · Korea, Republic of3CompletedMar 24, 2017302
NCT02761512Stomach Ulcer · Korea, Republic of3CompletedJul 26, 2018306
NCT02556021Non-Erosive Reflux Disease · Korea, Republic of3CompletedNov 1, 2016324
NCT02456935Erosive Esophagitis · Korea, Republic of3CompletedJul 2016280
NCT02052336Healthy · Korea, Republic of1CompletedJan 201424
NCT02028663Gastroesophageal Reflux · Korea, Republic of2CompletedMay 2014206
NCT01830309Healthy · Korea, Republic of1CompletedFeb 201324
NCT01473173Healthy · Korea, Republic of1CompletedAug 201259

How it is read

Names in the registry

  • “Tegoprazan”, 10 entries
  • “Tegoprazan 50 mg”, 5 entries
  • “BLI5100”, 3 entries
  • “Tegoprazan 50mg”, 3 entries
  • “CJ-12420 50mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.